- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,600 | 28.05.24 17:35:43 | -1,280 | -1,42% | 0,000 | 0,000 | 89,940 | 89,880 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 968,180 | 28.05.24 19:46:31 | -16,840 | -1,71% | 967,350 | 969,110 | 974,860 | 985,020 |
